FDA Requires New Eye-Related Risk Warnings for GLP-1 Receptor Agonist Drugs

The FDA is mandating updated labeling for all GLP-1 receptor agonist medications to include a warning about the potential for non-arteritic anterior ischaemic optic neuropathy (NAION), a rare condition causing sudden vision loss. This decision follows a comprehensive review of clinical trial, animal, post-marketing, and observational data, informing patients and healthcare providers of this newly identified risk.